Drugs / rhIL-11

Trials 2 · a red edge is where a trial was stopped

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00038922 ulcerative colitis Wyeth is now a wholly owned subsidiary of Pfizer Terminated No outcome recorded
Phase 41 trial
Phase 4 NCT02314273 Sep 2011 → Apr 2014 pancytopenia Shanghai Children's Medical Center Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT03823079 Comparator Feb → Sep 2019 colorectal carcinoma, thrombocytopenia Fudan University Unknown No outcome recorded
Phase 32 trials
Phase 3 NCT03720340 Comparator Oct 2018 → Aug 2021 nasopharyngeal carcinoma Zhejiang Cancer Hospital Unknown No outcome recorded
Phase 3 NCT01663441 Comparator Mar 2015 → Aug 2017 thrombocytopenia Beijing Northland Biotech. Co., Ltd. Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as rhIL-11 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02314273
3

NCT01663441

NCT00038922

NCT03823079

Known as IL-11 “Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.” NCT03720340
Known as Recombinant Human Interleukin-11 “A Randomized Phase II Study of Recombinant Human Thrombopoietin (Rh-TPO) and Recombinant Human Interleukin-11 (rhIL-11) for Recurrent Colorectal Cancer (CRC) Patients With...” NCT03823079
1

NCT03720340

Modality Protein / enzyme biologic “Orally Administered Recombinant Human Interleukin Eleven (rhIL-11)” NCT00038922
Route Oral orally delivered rhIL-11” NCT00038922